The Kandlelit-013 trial of calderasib plus Keytruda in adjuvant NSCLC will start in April.
ApexOnco Front Page
Recent articles
But now it must show that varseta-M can move into a registrational trial.
A new phase 3, Manifest-3, will start in April to support US filing.
Intismeran autogene’s Interpath-001 trial reads out this year.
New first-in-human study initiations feature yet more in vivo Car assets.
Armed with $75m the company takes a risky asset into the clinic.
The biotech licenses a China-developed anti-B7-H3 ADC.
The Japanese group’s $1.2bn deal with Innovent is by far the biggest of the fourth quarter.
